Probiotics to treat anal precancer (PROTECT trial)
Part of Cancer, Digestive system clinical trials.
This study tests if a probiotic called EXE-346 can help clear anal high-grade squamous intraepithelial lesions (HSIL), a precancerous condition, in people with HIV who are on effective antiretroviral therapy. If you have anal HSIL that wasn't fully removed by biopsy, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have anal HSIL (a precancerous spot) that was not completely removed by biopsy.
- You are on HIV treatment (antiretroviral therapy) for at least 3 months, with a viral load under 200.
- Your CD4 count (a measure of immune health) has never been below 200.
- You are generally in good health (able to do daily activities) and have normal blood counts.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tries to prevent anal cancer in men who have sex with men and are at higher risk due to HIV or PrEP use. It uses a special exam called high-resolution anoscopy to check for early signs.
This trial tests an artesunate ointment to treat high-grade anal precancer (HSIL) in people who do not have HIV. The goal is to see if the ointment can clear the abnormal cells caused by HPV.
This Phase 2 study tests whether a curcumin (a natural plant compound) cream/gel applied to the cervix can help treat cervical cell changes linked to HPV. It focuses on people with mild (LSIL) or recently treated severe (HSIL) precancer changes, aiming to reduce disease and improve healing.
This study is screening gay and bisexual men for anal cancer by taking a swab sample. It aims to find early signs of cancer so it can be treated early.
This study is looking at ways to screen for anal cancer in people who are at higher risk, such as those with weakened immune systems or a history of abnormal cells in the lower genital tract. It aims to find better methods for early detection.
This trial tests an experimental drug called ACU-D1 for people with HIV who have high-grade abnormal cell growth (HSIL) on their vulva or perianal area. The goal is to see if the drug can help treat these HPV-related lesions.
Hear when a new HPV-Related Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.